echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Dig Dis Sci: The role of fecal microbiota transplantation in removing hepatitis B surface antigen from patients with chronic hepatitis B

    Dig Dis Sci: The role of fecal microbiota transplantation in removing hepatitis B surface antigen from patients with chronic hepatitis B

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hepatitis B virus (HBV) is an important cause of chronic liver disease.


    Hepatitis B virus (HBV) is an important cause of chronic liver disease.


     

    In a meta-analysis, researchers found that even with the currently approved oral nucleoside analogues for the treatment of HBV-Entecavir (ETV) or Tenofovir Disoproxil fumarate (TDF), the treatment After 48 weeks, only a similar HBeAg seroconversion rate (10% VS 16%) was produced, which means that despite the use of nucleotide analogs, most patients have not undergone hepatitis B surface antigen seroconversion.


    immunity

     

     

    Researchers conducted this trial on HBeAg-positive patients who had received antiviral therapy for more than 1 year.


     

     

    Two groups of patients: the median age of the FMT group and the AVT group were both 29 years (P = 0.


     

     

    This study confirmed that FMT appears to be safe and potentially effective in terms of viral suppression and HBeAg clearance in HBeAg-positive CHB patients, but it still cannot replace drug therapy.


    This study confirmed that FMT appears to be safe and potentially effective in terms of viral suppression and HBeAg clearance in HBeAg-positive CHB patients, but it still cannot replace drug therapy.


     

    Original source:

    Ashish Chauhan.


    springer.
    com/article/10.
    1007/s10620-020-06246-x" target="_blank" rel="noopener">Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.